Company / EPS (Basic)
Apellis Pharmaceuticals, Inc. EPS (Basic) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$4.45
FY2025
5-year range
-$8.84 / -$4.45
FY2022-FY2025
Trend
+27.6%
vs FY2024
Sector context
#172 of 208
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s eps (basic) of $-4.45 is lower than 83% of companies in the Health Care sector (FY2025). Improved from $-8.84 to $-4.45 over the past 2 years.
Based on SEC 10-K filings.
-4.45 in FY2025.
Improved from $-8.84 to $-4.45 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 208This company -$4.45 Sector average -$0.87
▼
-411.1% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 27.6% year-over-year.
- Ranks #172 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.45 | +27.6% |
| FY2024 | -$6.15 | +30.4% |
| FY2023 | -$8.84 | -92.6% |
| FY2022 | -$4.59 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026